Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
US11932698B2 · kind B2 · utility
0Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2019 |
| Grant date | Mar 19, 2024 |
| Priority date | — |
| Expiry date | Sep 13, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-β receptor II (dnTGFβRII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.